Japan approval rush includes Xeljanz, Acofide, Nouriast and Onglyza
This article was originally published in Scrip
Less than two weeks after giving a preliminary nod to Xeljanz (tofacitinib), Japan has granted a formal approval to the novel Pfizer rheumatoid arthritis drug, only the second to be given worldwide after that in the US last November.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.